BridgeBio gets funding for drug launch; United buys into cell therapy
BridgeBio gets funding for drug launch; United buys into cell therapy (BioPharma Dive.)
BridgeBio Pharma
BridgeBio Pharma is a clinical-stage biotechnology company designing transformative medicines for patients with genetic diseases and cancers with clear genetic drivers. The company's pipeline includes infigratinib (FGFR-driven cholangiocarcinoma and other indications), acoramidis (ATTR-CM, approved 2024), and an achondroplasia therapy that has shown compelling growth and body-proportionality benefit in clinical data.
Company Info
Sector:Biotechnology / Genetic Disease
Headquarters:Palo Alto, California, USA
Founded:2015
Website:bridgebio.com/
Upcoming Milestones & Key Dates
Q3 2026
Earnings
Q2 2026 earnings and pipeline update
H2 2026
Clinical Trial
Achondroplasia therapy clinical updates and regulatory planning
Clinical Development Pipeline
Acoramidis (Attruby)
Target: TTR stabilizer (kinetic stabilizer)Infigratinib (Truseltiq)
Target: FGFR1-3 tyrosine kinase inhibitorAchondroplasia oral therapy (infigratinib-class or successor)
Target: FGFR3 pathway modulationRecent News
BridgeBio touts kidney benefits for Attruby, differentiating from amyloidosis competitors
BridgeBio Pharma highlights kidney-related benefits of its approved ATTR-CM drug Attruby, positioning the therapy to differentiate from competing amyloidosis treatments. (Source: BioSpace, 2026-07-06)
BridgeBio adds $1B as it prepares three more drug launches
BridgeBio adds $1B as it prepares three more drug launches
Sixth Street, KKR invest up to $1B to propel BridgeBio launches
Sixth Street, KKR invest up to $1B to propel BridgeBio launches. (Fierce Pharma.)
Leadership Team
Neil Kumar
Chief Executive Officer
Brian Stephenson
Chief Financial Officer
Dr. Jonathan Fox
Chief Medical Officer (Cardiometabolic)
Careers & Job Openings